• CytomX Therapeutics Inc CTMX.OQ CTMX.O is expected to show a fall in quarterly revenue when it reports results on March 6 for the period ending December 31 2024

• The South San Francisco California-based company is expected to report a 27.0% decrease in revenue to $19.417 million from $26.61 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.

• ​LSEG's mean analyst estimate for CytomX Therapeutics Inc is for a loss of 20 cents per share.

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

• The mean earnings estimate of analysts was unchanged in the last three months. ​

• Wall Street's median 12-month price target for CytomX Therapeutics Inc is $3.68​, above​ its last closing price of $0.65. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

This summary was machine generated March 4 at 21:08 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)